<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
<title>Merck.com - Product News</title>
<link>http://www.merck.com/newsroom/press_releases/product/</link>
<description>Merck.com - Product News</description>
<image>
	<title>Merck.com - Product News</title>
	<width>142</width>
	<height>42</height>
	<link>http://www.merck.com/newsroom/press_releases/product/</link>
	<url>http://www.merck.com/site_images/mercklogo-rss.jpg</url>
</image>
<item>
	<title>Merck Statement in Response to the FDA's June 12, 2009 Communication with Updated Information on Leukotriene Inhibitors, Including SINGULAIR&amp;reg; (montelukast sodium)</title>
	<guid isPermaLink="false">MerckStatementin06/12/2009</guid>
	<link>http://www.merck.com/newsroom/press_releases/product/2009_0612.html?src=rss</link>
	<pubDate>Fri, 12 Jun 2009 00:00:00 GMT</pubDate>
</item>
<item>
	<title>Initial Therapy with JANUMET&amp;trade; (sitagliptin/metformin) Provided Significantly Greater Blood Sugar Lowering Compared to Metformin Alone in Patients with Type 2 Diabetes </title>
	<guid isPermaLink="false">InitialTherapywi06/08/2009</guid>
	<link>http://www.merck.com/newsroom/press_releases/product/2009_0608.html?src=rss</link>
	<pubDate>Mon, 08 Jun 2009 00:00:00 GMT</pubDate>
</item>
<item>
	<title>In Investigational Studies, New Uses of JANUVIA&amp;trade; (sitagliptin) in Combination with Other Diabetes Medicines Resulted In Significant Blood Sugar-Lowering Efficacy for Patients with Type 2 Diabetes  </title>
	<guid isPermaLink="false">InInvestigationa06/06/2009</guid>
	<link>http://www.merck.com/newsroom/press_releases/product/2009_0606.html?src=rss</link>
	<pubDate>Sat, 06 Jun 2009 00:00:00 GMT</pubDate>
</item>
</channel>
</rss>